nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—CYP2E1—lung cancer	0.137	0.398	CbGaD
Fluvoxamine—CYP1A1—lung cancer	0.135	0.393	CbGaD
Fluvoxamine—ABCB1—lung cancer	0.072	0.209	CbGaD
Fluvoxamine—CYP1A1—Gefitinib—lung cancer	0.0253	0.059	CbGbCtD
Fluvoxamine—CYP3A5—Gefitinib—lung cancer	0.0152	0.0354	CbGbCtD
Fluvoxamine—CYP1A1—Erlotinib—lung cancer	0.015	0.0349	CbGbCtD
Fluvoxamine—CYP3A5—Teniposide—lung cancer	0.0147	0.0343	CbGbCtD
Fluvoxamine—CYP2C19—Gefitinib—lung cancer	0.0123	0.0285	CbGbCtD
Fluvoxamine—CYP2C19—Teniposide—lung cancer	0.0119	0.0277	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Paclitaxel—lung cancer	0.011	0.0255	CbGbCtD
Fluvoxamine—CYP3A7—Paclitaxel—lung cancer	0.011	0.0255	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Irinotecan—lung cancer	0.0108	0.0252	CbGbCtD
Fluvoxamine—CYP3A7—Irinotecan—lung cancer	0.0108	0.0252	CbGbCtD
Fluvoxamine—ABCB1—Topotecan—lung cancer	0.0108	0.0252	CbGbCtD
Fluvoxamine—CYP2B6—Irinotecan—lung cancer	0.0103	0.024	CbGbCtD
Fluvoxamine—CYP2C9—Gefitinib—lung cancer	0.0102	0.0237	CbGbCtD
Fluvoxamine—ABCB1—Gefitinib—lung cancer	0.00989	0.023	CbGbCtD
Fluvoxamine—CYP2C9—Teniposide—lung cancer	0.00988	0.023	CbGbCtD
Fluvoxamine—CYP2D6—Gefitinib—lung cancer	0.00932	0.0217	CbGbCtD
Fluvoxamine—CYP3A5—Crizotinib—lung cancer	0.00931	0.0217	CbGbCtD
Fluvoxamine—CYP3A5—Erlotinib—lung cancer	0.00898	0.0209	CbGbCtD
Fluvoxamine—CYP2B6—Cisplatin—lung cancer	0.00839	0.0196	CbGbCtD
Fluvoxamine—CYP2E1—Etoposide—lung cancer	0.00836	0.0195	CbGbCtD
Fluvoxamine—CYP3A5—Paclitaxel—lung cancer	0.00822	0.0192	CbGbCtD
Fluvoxamine—CYP3A5—Irinotecan—lung cancer	0.00811	0.0189	CbGbCtD
Fluvoxamine—CYP3A7—Docetaxel—lung cancer	0.00793	0.0185	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Docetaxel—lung cancer	0.00793	0.0185	CbGbCtD
Fluvoxamine—ABCB1—Vinorelbine—lung cancer	0.00762	0.0177	CbGbCtD
Fluvoxamine—CYP2D6—Vinorelbine—lung cancer	0.00718	0.0167	CbGbCtD
Fluvoxamine—CYP1A2—Erlotinib—lung cancer	0.00669	0.0156	CbGbCtD
Fluvoxamine—CYP3A5—Etoposide—lung cancer	0.0065	0.0151	CbGbCtD
Fluvoxamine—CYP3A4—Topotecan—lung cancer	0.00648	0.0151	CbGbCtD
Fluvoxamine—ABCB1—Crizotinib—lung cancer	0.00606	0.0141	CbGbCtD
Fluvoxamine—CYP3A5—Docetaxel—lung cancer	0.00594	0.0139	CbGbCtD
Fluvoxamine—CYP3A4—Gefitinib—lung cancer	0.00592	0.0138	CbGbCtD
Fluvoxamine—ABCB1—Gemcitabine—lung cancer	0.00592	0.0138	CbGbCtD
Fluvoxamine—ABCB1—Erlotinib—lung cancer	0.00585	0.0136	CbGbCtD
Fluvoxamine—CYP3A4—Teniposide—lung cancer	0.00574	0.0134	CbGbCtD
Fluvoxamine—CYP2B6—Doxorubicin—lung cancer	0.00563	0.0131	CbGbCtD
Fluvoxamine—CYP2C9—Paclitaxel—lung cancer	0.00551	0.0128	CbGbCtD
Fluvoxamine—CYP2D6—Erlotinib—lung cancer	0.00551	0.0128	CbGbCtD
Fluvoxamine—ABCB1—Paclitaxel—lung cancer	0.00535	0.0125	CbGbCtD
Fluvoxamine—ABCB1—Irinotecan—lung cancer	0.00528	0.0123	CbGbCtD
Fluvoxamine—CYP1A2—Etoposide—lung cancer	0.00484	0.0113	CbGbCtD
Fluvoxamine—ABCB1—Vinblastine—lung cancer	0.00469	0.0109	CbGbCtD
Fluvoxamine—CYP3A4—Vinorelbine—lung cancer	0.00456	0.0106	CbGbCtD
Fluvoxamine—CYP2C9—Cisplatin—lung cancer	0.00443	0.0103	CbGbCtD
Fluvoxamine—CYP2D6—Vinblastine—lung cancer	0.00442	0.0103	CbGbCtD
Fluvoxamine—ABCB1—Cisplatin—lung cancer	0.0043	0.01	CbGbCtD
Fluvoxamine—ABCB1—Etoposide—lung cancer	0.00423	0.00985	CbGbCtD
Fluvoxamine—ABCB1—Docetaxel—lung cancer	0.00387	0.00901	CbGbCtD
Fluvoxamine—CYP3A4—Crizotinib—lung cancer	0.00363	0.00846	CbGbCtD
Fluvoxamine—CYP3A4—Erlotinib—lung cancer	0.0035	0.00816	CbGbCtD
Fluvoxamine—CYP3A4—Paclitaxel—lung cancer	0.00321	0.00747	CbGbCtD
Fluvoxamine—CYP3A4—Irinotecan—lung cancer	0.00316	0.00737	CbGbCtD
Fluvoxamine—ABCB1—Doxorubicin—lung cancer	0.00288	0.00672	CbGbCtD
Fluvoxamine—CYP3A4—Vinblastine—lung cancer	0.00281	0.00655	CbGbCtD
Fluvoxamine—ABCB1—Methotrexate—lung cancer	0.00279	0.00651	CbGbCtD
Fluvoxamine—CYP2D6—Doxorubicin—lung cancer	0.00272	0.00633	CbGbCtD
Fluvoxamine—CYP3A4—Etoposide—lung cancer	0.00253	0.0059	CbGbCtD
Fluvoxamine—CYP3A4—Docetaxel—lung cancer	0.00232	0.0054	CbGbCtD
Fluvoxamine—CYP3A4—Doxorubicin—lung cancer	0.00173	0.00403	CbGbCtD
Fluvoxamine—SIGMAR1—mammary gland—lung cancer	9.96e-05	0.0801	CbGeAlD
Fluvoxamine—SLC6A3—respiratory system—lung cancer	7.29e-05	0.0587	CbGeAlD
Fluvoxamine—SLC6A4—respiratory system—lung cancer	6.68e-05	0.0538	CbGeAlD
Fluvoxamine—CYP2C9—mammary gland—lung cancer	6.44e-05	0.0518	CbGeAlD
Fluvoxamine—SIGMAR1—bronchus—lung cancer	5.46e-05	0.044	CbGeAlD
Fluvoxamine—SIGMAR1—trachea—lung cancer	4.91e-05	0.0395	CbGeAlD
Fluvoxamine—SIGMAR1—cardiac atrium—lung cancer	4.61e-05	0.0371	CbGeAlD
Fluvoxamine—CYP1A2—respiratory system—lung cancer	4.52e-05	0.0364	CbGeAlD
Fluvoxamine—CYP1A1—respiratory system—lung cancer	4.46e-05	0.0359	CbGeAlD
Fluvoxamine—CYP3A5—respiratory system—lung cancer	4.36e-05	0.0351	CbGeAlD
Fluvoxamine—CYP2B6—respiratory system—lung cancer	4.34e-05	0.0349	CbGeAlD
Fluvoxamine—CYP2E1—respiratory system—lung cancer	4.07e-05	0.0327	CbGeAlD
Fluvoxamine—SIGMAR1—bone marrow—lung cancer	3.89e-05	0.0313	CbGeAlD
Fluvoxamine—SLC6A3—lung—lung cancer	3.87e-05	0.0312	CbGeAlD
Fluvoxamine—CYP1A1—epithelium—lung cancer	3.73e-05	0.03	CbGeAlD
Fluvoxamine—CYP1A1—bronchus—lung cancer	3.67e-05	0.0295	CbGeAlD
Fluvoxamine—Pain—Paclitaxel—lung cancer	3.6e-05	0.000241	CcSEcCtD
Fluvoxamine—Constipation—Paclitaxel—lung cancer	3.6e-05	0.000241	CcSEcCtD
Fluvoxamine—Confusional state—Docetaxel—lung cancer	3.6e-05	0.000241	CcSEcCtD
Fluvoxamine—Pharyngitis—Methotrexate—lung cancer	3.6e-05	0.000241	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Methotrexate—lung cancer	3.58e-05	0.00024	CcSEcCtD
Fluvoxamine—Photosensitivity reaction—Doxorubicin—lung cancer	3.58e-05	0.00024	CcSEcCtD
Fluvoxamine—Oedema—Docetaxel—lung cancer	3.57e-05	0.000239	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Docetaxel—lung cancer	3.57e-05	0.000239	CcSEcCtD
Fluvoxamine—Weight increased—Doxorubicin—lung cancer	3.57e-05	0.000239	CcSEcCtD
Fluvoxamine—CYP2B6—bronchus—lung cancer	3.57e-05	0.0287	CbGeAlD
Fluvoxamine—Pruritus—Gemcitabine—lung cancer	3.56e-05	0.000238	CcSEcCtD
Fluvoxamine—Urethral disorder—Methotrexate—lung cancer	3.55e-05	0.000238	CcSEcCtD
Fluvoxamine—Infection—Docetaxel—lung cancer	3.55e-05	0.000238	CcSEcCtD
Fluvoxamine—SLC6A4—lung—lung cancer	3.55e-05	0.0286	CbGeAlD
Fluvoxamine—Weight decreased—Doxorubicin—lung cancer	3.55e-05	0.000237	CcSEcCtD
Fluvoxamine—Feeling abnormal—Etoposide—lung cancer	3.54e-05	0.000237	CcSEcCtD
Fluvoxamine—Hyperglycaemia—Doxorubicin—lung cancer	3.54e-05	0.000237	CcSEcCtD
Fluvoxamine—Diarrhoea—Irinotecan—lung cancer	3.54e-05	0.000237	CcSEcCtD
Fluvoxamine—SIGMAR1—lung—lung cancer	3.52e-05	0.0284	CbGeAlD
Fluvoxamine—Pneumonia—Doxorubicin—lung cancer	3.52e-05	0.000235	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Etoposide—lung cancer	3.52e-05	0.000235	CcSEcCtD
Fluvoxamine—Shock—Docetaxel—lung cancer	3.52e-05	0.000235	CcSEcCtD
Fluvoxamine—Nervous system disorder—Docetaxel—lung cancer	3.5e-05	0.000234	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Docetaxel—lung cancer	3.5e-05	0.000234	CcSEcCtD
Fluvoxamine—Drowsiness—Doxorubicin—lung cancer	3.5e-05	0.000234	CcSEcCtD
Fluvoxamine—Visual impairment—Methotrexate—lung cancer	3.49e-05	0.000234	CcSEcCtD
Fluvoxamine—Tachycardia—Docetaxel—lung cancer	3.49e-05	0.000233	CcSEcCtD
Fluvoxamine—Feeling abnormal—Paclitaxel—lung cancer	3.47e-05	0.000232	CcSEcCtD
Fluvoxamine—Stevens-Johnson syndrome—Doxorubicin—lung cancer	3.47e-05	0.000232	CcSEcCtD
Fluvoxamine—Hypersensitivity—Cisplatin—lung cancer	3.46e-05	0.000231	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Paclitaxel—lung cancer	3.45e-05	0.000231	CcSEcCtD
Fluvoxamine—Diarrhoea—Gemcitabine—lung cancer	3.44e-05	0.000231	CcSEcCtD
Fluvoxamine—Renal failure—Doxorubicin—lung cancer	3.44e-05	0.00023	CcSEcCtD
Fluvoxamine—Erythema multiforme—Methotrexate—lung cancer	3.43e-05	0.000229	CcSEcCtD
Fluvoxamine—Neuropathy peripheral—Doxorubicin—lung cancer	3.43e-05	0.000229	CcSEcCtD
Fluvoxamine—Dizziness—Irinotecan—lung cancer	3.42e-05	0.000229	CcSEcCtD
Fluvoxamine—Urticaria—Etoposide—lung cancer	3.42e-05	0.000229	CcSEcCtD
Fluvoxamine—Stomatitis—Doxorubicin—lung cancer	3.41e-05	0.000228	CcSEcCtD
Fluvoxamine—Jaundice—Doxorubicin—lung cancer	3.41e-05	0.000228	CcSEcCtD
Fluvoxamine—Anorexia—Docetaxel—lung cancer	3.41e-05	0.000228	CcSEcCtD
Fluvoxamine—Abdominal pain—Etoposide—lung cancer	3.4e-05	0.000227	CcSEcCtD
Fluvoxamine—Body temperature increased—Etoposide—lung cancer	3.4e-05	0.000227	CcSEcCtD
Fluvoxamine—Urinary tract infection—Doxorubicin—lung cancer	3.4e-05	0.000227	CcSEcCtD
Fluvoxamine—Conjunctivitis—Doxorubicin—lung cancer	3.4e-05	0.000227	CcSEcCtD
Fluvoxamine—Eye disorder—Methotrexate—lung cancer	3.39e-05	0.000227	CcSEcCtD
Fluvoxamine—Tinnitus—Methotrexate—lung cancer	3.38e-05	0.000226	CcSEcCtD
Fluvoxamine—Asthenia—Cisplatin—lung cancer	3.37e-05	0.000225	CcSEcCtD
Fluvoxamine—Cardiac disorder—Methotrexate—lung cancer	3.36e-05	0.000225	CcSEcCtD
Fluvoxamine—Sweating—Doxorubicin—lung cancer	3.35e-05	0.000224	CcSEcCtD
Fluvoxamine—Urticaria—Paclitaxel—lung cancer	3.35e-05	0.000224	CcSEcCtD
Fluvoxamine—Hypotension—Docetaxel—lung cancer	3.34e-05	0.000223	CcSEcCtD
Fluvoxamine—Haematuria—Doxorubicin—lung cancer	3.33e-05	0.000223	CcSEcCtD
Fluvoxamine—Abdominal pain—Paclitaxel—lung cancer	3.33e-05	0.000223	CcSEcCtD
Fluvoxamine—Body temperature increased—Paclitaxel—lung cancer	3.33e-05	0.000223	CcSEcCtD
Fluvoxamine—Hepatobiliary disease—Doxorubicin—lung cancer	3.31e-05	0.000221	CcSEcCtD
Fluvoxamine—Epistaxis—Doxorubicin—lung cancer	3.3e-05	0.000221	CcSEcCtD
Fluvoxamine—CYP1A1—trachea—lung cancer	3.3e-05	0.0265	CbGeAlD
Fluvoxamine—Angiopathy—Methotrexate—lung cancer	3.29e-05	0.00022	CcSEcCtD
Fluvoxamine—Vomiting—Irinotecan—lung cancer	3.29e-05	0.00022	CcSEcCtD
Fluvoxamine—Sinusitis—Doxorubicin—lung cancer	3.28e-05	0.000219	CcSEcCtD
Fluvoxamine—Agranulocytosis—Doxorubicin—lung cancer	3.26e-05	0.000218	CcSEcCtD
Fluvoxamine—Rash—Irinotecan—lung cancer	3.26e-05	0.000218	CcSEcCtD
Fluvoxamine—Dermatitis—Irinotecan—lung cancer	3.26e-05	0.000218	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Docetaxel—lung cancer	3.26e-05	0.000218	CcSEcCtD
Fluvoxamine—Chills—Methotrexate—lung cancer	3.25e-05	0.000218	CcSEcCtD
Fluvoxamine—Headache—Irinotecan—lung cancer	3.24e-05	0.000217	CcSEcCtD
Fluvoxamine—Insomnia—Docetaxel—lung cancer	3.23e-05	0.000216	CcSEcCtD
Fluvoxamine—Diarrhoea—Cisplatin—lung cancer	3.21e-05	0.000215	CcSEcCtD
Fluvoxamine—Paraesthesia—Docetaxel—lung cancer	3.21e-05	0.000215	CcSEcCtD
Fluvoxamine—Alopecia—Methotrexate—lung cancer	3.2e-05	0.000214	CcSEcCtD
Fluvoxamine—Vomiting—Gemcitabine—lung cancer	3.2e-05	0.000214	CcSEcCtD
Fluvoxamine—Bradycardia—Doxorubicin—lung cancer	3.2e-05	0.000214	CcSEcCtD
Fluvoxamine—Dyspnoea—Docetaxel—lung cancer	3.19e-05	0.000213	CcSEcCtD
Fluvoxamine—Somnolence—Docetaxel—lung cancer	3.18e-05	0.000213	CcSEcCtD
Fluvoxamine—Mental disorder—Methotrexate—lung cancer	3.18e-05	0.000212	CcSEcCtD
Fluvoxamine—Rash—Gemcitabine—lung cancer	3.17e-05	0.000212	CcSEcCtD
Fluvoxamine—Dermatitis—Gemcitabine—lung cancer	3.17e-05	0.000212	CcSEcCtD
Fluvoxamine—Hypersensitivity—Etoposide—lung cancer	3.17e-05	0.000212	CcSEcCtD
Fluvoxamine—Malnutrition—Methotrexate—lung cancer	3.16e-05	0.000211	CcSEcCtD
Fluvoxamine—Haemoglobin—Doxorubicin—lung cancer	3.15e-05	0.000211	CcSEcCtD
Fluvoxamine—Headache—Gemcitabine—lung cancer	3.15e-05	0.000211	CcSEcCtD
Fluvoxamine—Rhinitis—Doxorubicin—lung cancer	3.15e-05	0.000211	CcSEcCtD
Fluvoxamine—Dyspepsia—Docetaxel—lung cancer	3.15e-05	0.00021	CcSEcCtD
Fluvoxamine—Hepatitis—Doxorubicin—lung cancer	3.14e-05	0.00021	CcSEcCtD
Fluvoxamine—Haemorrhage—Doxorubicin—lung cancer	3.14e-05	0.00021	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Doxorubicin—lung cancer	3.12e-05	0.000209	CcSEcCtD
Fluvoxamine—Pharyngitis—Doxorubicin—lung cancer	3.11e-05	0.000208	CcSEcCtD
Fluvoxamine—Decreased appetite—Docetaxel—lung cancer	3.11e-05	0.000208	CcSEcCtD
Fluvoxamine—Hypersensitivity—Paclitaxel—lung cancer	3.11e-05	0.000208	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Doxorubicin—lung cancer	3.1e-05	0.000207	CcSEcCtD
Fluvoxamine—CYP1A1—cardiac atrium—lung cancer	3.1e-05	0.0249	CbGeAlD
Fluvoxamine—Oedema peripheral—Doxorubicin—lung cancer	3.09e-05	0.000207	CcSEcCtD
Fluvoxamine—Dysgeusia—Methotrexate—lung cancer	3.09e-05	0.000207	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Docetaxel—lung cancer	3.08e-05	0.000206	CcSEcCtD
Fluvoxamine—Asthenia—Etoposide—lung cancer	3.08e-05	0.000206	CcSEcCtD
Fluvoxamine—Fatigue—Docetaxel—lung cancer	3.08e-05	0.000206	CcSEcCtD
Fluvoxamine—Urethral disorder—Doxorubicin—lung cancer	3.08e-05	0.000206	CcSEcCtD
Fluvoxamine—Nausea—Irinotecan—lung cancer	3.07e-05	0.000205	CcSEcCtD
Fluvoxamine—Pain—Docetaxel—lung cancer	3.06e-05	0.000204	CcSEcCtD
Fluvoxamine—Constipation—Docetaxel—lung cancer	3.06e-05	0.000204	CcSEcCtD
Fluvoxamine—Back pain—Methotrexate—lung cancer	3.05e-05	0.000204	CcSEcCtD
Fluvoxamine—Pruritus—Etoposide—lung cancer	3.04e-05	0.000204	CcSEcCtD
Fluvoxamine—Visual impairment—Doxorubicin—lung cancer	3.02e-05	0.000202	CcSEcCtD
Fluvoxamine—Asthenia—Paclitaxel—lung cancer	3.02e-05	0.000202	CcSEcCtD
Fluvoxamine—Nausea—Gemcitabine—lung cancer	2.99e-05	0.0002	CcSEcCtD
Fluvoxamine—Vomiting—Cisplatin—lung cancer	2.98e-05	0.0002	CcSEcCtD
Fluvoxamine—Pruritus—Paclitaxel—lung cancer	2.98e-05	0.0002	CcSEcCtD
Fluvoxamine—Vision blurred—Methotrexate—lung cancer	2.97e-05	0.000199	CcSEcCtD
Fluvoxamine—Erythema multiforme—Doxorubicin—lung cancer	2.97e-05	0.000199	CcSEcCtD
Fluvoxamine—Rash—Cisplatin—lung cancer	2.96e-05	0.000198	CcSEcCtD
Fluvoxamine—Dermatitis—Cisplatin—lung cancer	2.96e-05	0.000198	CcSEcCtD
Fluvoxamine—Feeling abnormal—Docetaxel—lung cancer	2.94e-05	0.000197	CcSEcCtD
Fluvoxamine—Diarrhoea—Etoposide—lung cancer	2.94e-05	0.000197	CcSEcCtD
Fluvoxamine—Eye disorder—Doxorubicin—lung cancer	2.93e-05	0.000196	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Methotrexate—lung cancer	2.93e-05	0.000196	CcSEcCtD
Fluvoxamine—Tinnitus—Doxorubicin—lung cancer	2.93e-05	0.000196	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Docetaxel—lung cancer	2.92e-05	0.000196	CcSEcCtD
Fluvoxamine—Anaemia—Methotrexate—lung cancer	2.92e-05	0.000195	CcSEcCtD
Fluvoxamine—Cardiac disorder—Doxorubicin—lung cancer	2.91e-05	0.000195	CcSEcCtD
Fluvoxamine—Diarrhoea—Paclitaxel—lung cancer	2.88e-05	0.000193	CcSEcCtD
Fluvoxamine—Angiopathy—Doxorubicin—lung cancer	2.85e-05	0.000191	CcSEcCtD
Fluvoxamine—Malaise—Methotrexate—lung cancer	2.85e-05	0.00019	CcSEcCtD
Fluvoxamine—Dizziness—Etoposide—lung cancer	2.84e-05	0.00019	CcSEcCtD
Fluvoxamine—Vertigo—Methotrexate—lung cancer	2.83e-05	0.00019	CcSEcCtD
Fluvoxamine—Body temperature increased—Docetaxel—lung cancer	2.82e-05	0.000189	CcSEcCtD
Fluvoxamine—Abdominal pain—Docetaxel—lung cancer	2.82e-05	0.000189	CcSEcCtD
Fluvoxamine—Leukopenia—Methotrexate—lung cancer	2.82e-05	0.000189	CcSEcCtD
Fluvoxamine—Chills—Doxorubicin—lung cancer	2.82e-05	0.000188	CcSEcCtD
Fluvoxamine—Arrhythmia—Doxorubicin—lung cancer	2.8e-05	0.000188	CcSEcCtD
Fluvoxamine—Dizziness—Paclitaxel—lung cancer	2.79e-05	0.000187	CcSEcCtD
Fluvoxamine—Nausea—Cisplatin—lung cancer	2.79e-05	0.000187	CcSEcCtD
Fluvoxamine—Alopecia—Doxorubicin—lung cancer	2.77e-05	0.000186	CcSEcCtD
Fluvoxamine—Cough—Methotrexate—lung cancer	2.75e-05	0.000184	CcSEcCtD
Fluvoxamine—Mental disorder—Doxorubicin—lung cancer	2.75e-05	0.000184	CcSEcCtD
Fluvoxamine—Convulsion—Methotrexate—lung cancer	2.73e-05	0.000183	CcSEcCtD
Fluvoxamine—Vomiting—Etoposide—lung cancer	2.73e-05	0.000183	CcSEcCtD
Fluvoxamine—Malnutrition—Doxorubicin—lung cancer	2.73e-05	0.000183	CcSEcCtD
Fluvoxamine—Rash—Etoposide—lung cancer	2.71e-05	0.000181	CcSEcCtD
Fluvoxamine—Dermatitis—Etoposide—lung cancer	2.71e-05	0.000181	CcSEcCtD
Fluvoxamine—Headache—Etoposide—lung cancer	2.69e-05	0.00018	CcSEcCtD
Fluvoxamine—Flatulence—Doxorubicin—lung cancer	2.69e-05	0.00018	CcSEcCtD
Fluvoxamine—Chest pain—Methotrexate—lung cancer	2.69e-05	0.00018	CcSEcCtD
Fluvoxamine—Arthralgia—Methotrexate—lung cancer	2.69e-05	0.00018	CcSEcCtD
Fluvoxamine—Myalgia—Methotrexate—lung cancer	2.69e-05	0.00018	CcSEcCtD
Fluvoxamine—Tension—Doxorubicin—lung cancer	2.68e-05	0.000179	CcSEcCtD
Fluvoxamine—Vomiting—Paclitaxel—lung cancer	2.68e-05	0.000179	CcSEcCtD
Fluvoxamine—Dysgeusia—Doxorubicin—lung cancer	2.68e-05	0.000179	CcSEcCtD
Fluvoxamine—Rash—Paclitaxel—lung cancer	2.66e-05	0.000178	CcSEcCtD
Fluvoxamine—Dermatitis—Paclitaxel—lung cancer	2.66e-05	0.000178	CcSEcCtD
Fluvoxamine—Discomfort—Methotrexate—lung cancer	2.65e-05	0.000178	CcSEcCtD
Fluvoxamine—Nervousness—Doxorubicin—lung cancer	2.65e-05	0.000178	CcSEcCtD
Fluvoxamine—Back pain—Doxorubicin—lung cancer	2.64e-05	0.000177	CcSEcCtD
Fluvoxamine—Headache—Paclitaxel—lung cancer	2.64e-05	0.000177	CcSEcCtD
Fluvoxamine—Hypersensitivity—Docetaxel—lung cancer	2.63e-05	0.000176	CcSEcCtD
Fluvoxamine—Muscle spasms—Doxorubicin—lung cancer	2.63e-05	0.000176	CcSEcCtD
Fluvoxamine—Confusional state—Methotrexate—lung cancer	2.6e-05	0.000174	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Methotrexate—lung cancer	2.58e-05	0.000172	CcSEcCtD
Fluvoxamine—Vision blurred—Doxorubicin—lung cancer	2.57e-05	0.000172	CcSEcCtD
Fluvoxamine—Asthenia—Docetaxel—lung cancer	2.56e-05	0.000172	CcSEcCtD
Fluvoxamine—Infection—Methotrexate—lung cancer	2.56e-05	0.000171	CcSEcCtD
Fluvoxamine—Nausea—Etoposide—lung cancer	2.55e-05	0.000171	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Doxorubicin—lung cancer	2.53e-05	0.00017	CcSEcCtD
Fluvoxamine—Pruritus—Docetaxel—lung cancer	2.53e-05	0.000169	CcSEcCtD
Fluvoxamine—Nervous system disorder—Methotrexate—lung cancer	2.53e-05	0.000169	CcSEcCtD
Fluvoxamine—Anaemia—Doxorubicin—lung cancer	2.53e-05	0.000169	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Methotrexate—lung cancer	2.52e-05	0.000169	CcSEcCtD
Fluvoxamine—Agitation—Doxorubicin—lung cancer	2.51e-05	0.000168	CcSEcCtD
Fluvoxamine—Nausea—Paclitaxel—lung cancer	2.5e-05	0.000168	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Methotrexate—lung cancer	2.49e-05	0.000167	CcSEcCtD
Fluvoxamine—Malaise—Doxorubicin—lung cancer	2.46e-05	0.000165	CcSEcCtD
Fluvoxamine—Vertigo—Doxorubicin—lung cancer	2.45e-05	0.000164	CcSEcCtD
Fluvoxamine—Anorexia—Methotrexate—lung cancer	2.45e-05	0.000164	CcSEcCtD
Fluvoxamine—Syncope—Doxorubicin—lung cancer	2.45e-05	0.000164	CcSEcCtD
Fluvoxamine—Leukopenia—Doxorubicin—lung cancer	2.45e-05	0.000164	CcSEcCtD
Fluvoxamine—Diarrhoea—Docetaxel—lung cancer	2.44e-05	0.000164	CcSEcCtD
Fluvoxamine—Palpitations—Doxorubicin—lung cancer	2.41e-05	0.000162	CcSEcCtD
Fluvoxamine—SIGMAR1—lymph node—lung cancer	2.41e-05	0.0194	CbGeAlD
Fluvoxamine—Hypotension—Methotrexate—lung cancer	2.41e-05	0.000161	CcSEcCtD
Fluvoxamine—CYP1A2—lung—lung cancer	2.4e-05	0.0193	CbGeAlD
Fluvoxamine—Loss of consciousness—Doxorubicin—lung cancer	2.4e-05	0.000161	CcSEcCtD
Fluvoxamine—Cough—Doxorubicin—lung cancer	2.38e-05	0.00016	CcSEcCtD
Fluvoxamine—CYP1A1—lung—lung cancer	2.37e-05	0.0191	CbGeAlD
Fluvoxamine—Convulsion—Doxorubicin—lung cancer	2.37e-05	0.000158	CcSEcCtD
Fluvoxamine—Dizziness—Docetaxel—lung cancer	2.36e-05	0.000158	CcSEcCtD
Fluvoxamine—Hypertension—Doxorubicin—lung cancer	2.36e-05	0.000158	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Methotrexate—lung cancer	2.35e-05	0.000157	CcSEcCtD
Fluvoxamine—Insomnia—Methotrexate—lung cancer	2.33e-05	0.000156	CcSEcCtD
Fluvoxamine—Chest pain—Doxorubicin—lung cancer	2.33e-05	0.000156	CcSEcCtD
Fluvoxamine—Myalgia—Doxorubicin—lung cancer	2.33e-05	0.000156	CcSEcCtD
Fluvoxamine—Arthralgia—Doxorubicin—lung cancer	2.33e-05	0.000156	CcSEcCtD
Fluvoxamine—Anxiety—Doxorubicin—lung cancer	2.32e-05	0.000155	CcSEcCtD
Fluvoxamine—ABCB1—respiratory system—lung cancer	2.32e-05	0.0186	CbGeAlD
Fluvoxamine—CYP3A5—lung—lung cancer	2.32e-05	0.0186	CbGeAlD
Fluvoxamine—Paraesthesia—Methotrexate—lung cancer	2.31e-05	0.000155	CcSEcCtD
Fluvoxamine—CYP2B6—lung—lung cancer	2.3e-05	0.0185	CbGeAlD
Fluvoxamine—Discomfort—Doxorubicin—lung cancer	2.3e-05	0.000154	CcSEcCtD
Fluvoxamine—Dyspnoea—Methotrexate—lung cancer	2.3e-05	0.000154	CcSEcCtD
Fluvoxamine—Somnolence—Methotrexate—lung cancer	2.29e-05	0.000153	CcSEcCtD
Fluvoxamine—Dry mouth—Doxorubicin—lung cancer	2.27e-05	0.000152	CcSEcCtD
Fluvoxamine—Vomiting—Docetaxel—lung cancer	2.27e-05	0.000152	CcSEcCtD
Fluvoxamine—Dyspepsia—Methotrexate—lung cancer	2.27e-05	0.000152	CcSEcCtD
Fluvoxamine—Rash—Docetaxel—lung cancer	2.25e-05	0.000151	CcSEcCtD
Fluvoxamine—Dermatitis—Docetaxel—lung cancer	2.25e-05	0.000151	CcSEcCtD
Fluvoxamine—Confusional state—Doxorubicin—lung cancer	2.25e-05	0.00015	CcSEcCtD
Fluvoxamine—Decreased appetite—Methotrexate—lung cancer	2.24e-05	0.00015	CcSEcCtD
Fluvoxamine—Headache—Docetaxel—lung cancer	2.24e-05	0.00015	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Doxorubicin—lung cancer	2.23e-05	0.000149	CcSEcCtD
Fluvoxamine—Oedema—Doxorubicin—lung cancer	2.23e-05	0.000149	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Methotrexate—lung cancer	2.22e-05	0.000149	CcSEcCtD
Fluvoxamine—Fatigue—Methotrexate—lung cancer	2.22e-05	0.000149	CcSEcCtD
Fluvoxamine—Infection—Doxorubicin—lung cancer	2.22e-05	0.000148	CcSEcCtD
Fluvoxamine—Pain—Methotrexate—lung cancer	2.2e-05	0.000147	CcSEcCtD
Fluvoxamine—Shock—Doxorubicin—lung cancer	2.19e-05	0.000147	CcSEcCtD
Fluvoxamine—Nervous system disorder—Doxorubicin—lung cancer	2.19e-05	0.000146	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Doxorubicin—lung cancer	2.18e-05	0.000146	CcSEcCtD
Fluvoxamine—Tachycardia—Doxorubicin—lung cancer	2.18e-05	0.000146	CcSEcCtD
Fluvoxamine—CYP2E1—lung—lung cancer	2.16e-05	0.0174	CbGeAlD
Fluvoxamine—Hyperhidrosis—Doxorubicin—lung cancer	2.16e-05	0.000144	CcSEcCtD
Fluvoxamine—Anorexia—Doxorubicin—lung cancer	2.13e-05	0.000142	CcSEcCtD
Fluvoxamine—Nausea—Docetaxel—lung cancer	2.12e-05	0.000142	CcSEcCtD
Fluvoxamine—Feeling abnormal—Methotrexate—lung cancer	2.12e-05	0.000142	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Methotrexate—lung cancer	2.11e-05	0.000141	CcSEcCtD
Fluvoxamine—Hypotension—Doxorubicin—lung cancer	2.08e-05	0.000139	CcSEcCtD
Fluvoxamine—Urticaria—Methotrexate—lung cancer	2.05e-05	0.000137	CcSEcCtD
Fluvoxamine—Abdominal pain—Methotrexate—lung cancer	2.04e-05	0.000136	CcSEcCtD
Fluvoxamine—Body temperature increased—Methotrexate—lung cancer	2.04e-05	0.000136	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Doxorubicin—lung cancer	2.03e-05	0.000136	CcSEcCtD
Fluvoxamine—Insomnia—Doxorubicin—lung cancer	2.02e-05	0.000135	CcSEcCtD
Fluvoxamine—Paraesthesia—Doxorubicin—lung cancer	2e-05	0.000134	CcSEcCtD
Fluvoxamine—Dyspnoea—Doxorubicin—lung cancer	1.99e-05	0.000133	CcSEcCtD
Fluvoxamine—Somnolence—Doxorubicin—lung cancer	1.98e-05	0.000133	CcSEcCtD
Fluvoxamine—Dyspepsia—Doxorubicin—lung cancer	1.96e-05	0.000131	CcSEcCtD
Fluvoxamine—Decreased appetite—Doxorubicin—lung cancer	1.94e-05	0.00013	CcSEcCtD
Fluvoxamine—ABCB1—epithelium—lung cancer	1.94e-05	0.0156	CbGeAlD
Fluvoxamine—Gastrointestinal disorder—Doxorubicin—lung cancer	1.93e-05	0.000129	CcSEcCtD
Fluvoxamine—Fatigue—Doxorubicin—lung cancer	1.92e-05	0.000129	CcSEcCtD
Fluvoxamine—Pain—Doxorubicin—lung cancer	1.91e-05	0.000128	CcSEcCtD
Fluvoxamine—Constipation—Doxorubicin—lung cancer	1.91e-05	0.000128	CcSEcCtD
Fluvoxamine—Hypersensitivity—Methotrexate—lung cancer	1.9e-05	0.000127	CcSEcCtD
Fluvoxamine—Asthenia—Methotrexate—lung cancer	1.85e-05	0.000124	CcSEcCtD
Fluvoxamine—Feeling abnormal—Doxorubicin—lung cancer	1.84e-05	0.000123	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Doxorubicin—lung cancer	1.82e-05	0.000122	CcSEcCtD
Fluvoxamine—Pruritus—Methotrexate—lung cancer	1.82e-05	0.000122	CcSEcCtD
Fluvoxamine—Urticaria—Doxorubicin—lung cancer	1.77e-05	0.000119	CcSEcCtD
Fluvoxamine—Abdominal pain—Doxorubicin—lung cancer	1.76e-05	0.000118	CcSEcCtD
Fluvoxamine—Body temperature increased—Doxorubicin—lung cancer	1.76e-05	0.000118	CcSEcCtD
Fluvoxamine—Diarrhoea—Methotrexate—lung cancer	1.76e-05	0.000118	CcSEcCtD
Fluvoxamine—ABCB1—trachea—lung cancer	1.71e-05	0.0138	CbGeAlD
Fluvoxamine—Dizziness—Methotrexate—lung cancer	1.7e-05	0.000114	CcSEcCtD
Fluvoxamine—Hypersensitivity—Doxorubicin—lung cancer	1.64e-05	0.00011	CcSEcCtD
Fluvoxamine—Vomiting—Methotrexate—lung cancer	1.64e-05	0.00011	CcSEcCtD
Fluvoxamine—Rash—Methotrexate—lung cancer	1.62e-05	0.000109	CcSEcCtD
Fluvoxamine—Dermatitis—Methotrexate—lung cancer	1.62e-05	0.000109	CcSEcCtD
Fluvoxamine—CYP1A1—lymph node—lung cancer	1.62e-05	0.013	CbGeAlD
Fluvoxamine—Headache—Methotrexate—lung cancer	1.61e-05	0.000108	CcSEcCtD
Fluvoxamine—Asthenia—Doxorubicin—lung cancer	1.6e-05	0.000107	CcSEcCtD
Fluvoxamine—Pruritus—Doxorubicin—lung cancer	1.58e-05	0.000106	CcSEcCtD
Fluvoxamine—Nausea—Methotrexate—lung cancer	1.53e-05	0.000102	CcSEcCtD
Fluvoxamine—Diarrhoea—Doxorubicin—lung cancer	1.53e-05	0.000102	CcSEcCtD
Fluvoxamine—Dizziness—Doxorubicin—lung cancer	1.47e-05	9.87e-05	CcSEcCtD
Fluvoxamine—Vomiting—Doxorubicin—lung cancer	1.42e-05	9.49e-05	CcSEcCtD
Fluvoxamine—Rash—Doxorubicin—lung cancer	1.41e-05	9.41e-05	CcSEcCtD
Fluvoxamine—Dermatitis—Doxorubicin—lung cancer	1.4e-05	9.4e-05	CcSEcCtD
Fluvoxamine—Headache—Doxorubicin—lung cancer	1.4e-05	9.35e-05	CcSEcCtD
Fluvoxamine—ABCB1—bone marrow—lung cancer	1.36e-05	0.0109	CbGeAlD
Fluvoxamine—Nausea—Doxorubicin—lung cancer	1.32e-05	8.86e-05	CcSEcCtD
Fluvoxamine—ABCB1—lung—lung cancer	1.23e-05	0.0099	CbGeAlD
Fluvoxamine—ABCB1—lymph node—lung cancer	8.42e-06	0.00677	CbGeAlD
Fluvoxamine—CYP2C19—Metabolism—NQO1—lung cancer	4.17e-06	5.53e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	4.15e-06	5.51e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GSTM1—lung cancer	4.14e-06	5.5e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CAT—lung cancer	4.13e-06	5.49e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GSTM1—lung cancer	4.13e-06	5.48e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CYP2E1—lung cancer	4.11e-06	5.46e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—EP300—lung cancer	4.11e-06	5.46e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ADCY1—lung cancer	4.11e-06	5.45e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ABCG2—lung cancer	4.11e-06	5.45e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	4.08e-06	5.42e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTA2—lung cancer	4.08e-06	5.41e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—NQO1—lung cancer	4.07e-06	5.4e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	4.04e-06	5.37e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—POMC—lung cancer	4.04e-06	5.36e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—HPGDS—lung cancer	4.03e-06	5.35e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ENO2—lung cancer	4.03e-06	5.35e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ABCB1—lung cancer	4.02e-06	5.34e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CYP1A1—lung cancer	4.01e-06	5.32e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PPP2R1B—lung cancer	4e-06	5.31e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—ERCC2—lung cancer	3.97e-06	5.28e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—lung cancer	3.95e-06	5.24e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—TYMS—lung cancer	3.95e-06	5.24e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CREBBP—lung cancer	3.93e-06	5.22e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTA1—lung cancer	3.93e-06	5.22e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CYP1A1—lung cancer	3.92e-06	5.21e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CYP1A1—lung cancer	3.92e-06	5.2e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTT1—lung cancer	3.91e-06	5.19e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GSTM1—lung cancer	3.9e-06	5.18e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—ERCC2—lung cancer	3.89e-06	5.17e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ABCC3—lung cancer	3.89e-06	5.16e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—ERCC2—lung cancer	3.88e-06	5.16e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—RAF1—lung cancer	3.88e-06	5.15e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CYP2E1—lung cancer	3.88e-06	5.15e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP2A6—lung cancer	3.86e-06	5.13e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GCLC—lung cancer	3.86e-06	5.13e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	3.85e-06	5.11e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CYP2E1—lung cancer	3.84e-06	5.1e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—NQO1—lung cancer	3.83e-06	5.09e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—NQO1—lung cancer	3.8e-06	5.04e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—AKR1C1—lung cancer	3.77e-06	5e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—STK11—lung cancer	3.76e-06	4.99e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PIK3CD—lung cancer	3.73e-06	4.95e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	3.72e-06	4.94e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	3.69e-06	4.89e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—ALB—lung cancer	3.68e-06	4.89e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ERCC2—lung cancer	3.67e-06	4.87e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—STK11—lung cancer	3.67e-06	4.87e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ENO1—lung cancer	3.66e-06	4.86e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—UGT1A1—lung cancer	3.66e-06	4.85e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	3.65e-06	4.84e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—lung cancer	3.6e-06	4.78e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—lung cancer	3.53e-06	4.68e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GNG11—lung cancer	3.53e-06	4.68e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSTP1—lung cancer	3.48e-06	4.61e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—STK11—lung cancer	3.45e-06	4.59e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—APOA1—lung cancer	3.44e-06	4.56e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—STK11—lung cancer	3.42e-06	4.55e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSTP1—lung cancer	3.39e-06	4.5e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CAT—lung cancer	3.38e-06	4.49e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—APOA1—lung cancer	3.37e-06	4.47e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—lung cancer	3.36e-06	4.46e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—APOA1—lung cancer	3.36e-06	4.46e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ALDOA—lung cancer	3.36e-06	4.46e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CAT—lung cancer	3.3e-06	4.38e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ABCB1—lung cancer	3.29e-06	4.37e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP2E1—lung cancer	3.28e-06	4.36e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NCOA3—lung cancer	3.26e-06	4.33e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PIK3CB—lung cancer	3.25e-06	4.32e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—NQO1—lung cancer	3.25e-06	4.31e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—TYMS—lung cancer	3.23e-06	4.29e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PTGS2—lung cancer	3.22e-06	4.28e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	3.21e-06	4.27e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSTP1—lung cancer	3.2e-06	4.24e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSTM1—lung cancer	3.19e-06	4.24e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	3.18e-06	4.22e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—APOA1—lung cancer	3.17e-06	4.21e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ADCY1—lung cancer	3.17e-06	4.21e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ABCG2—lung cancer	3.17e-06	4.21e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTP1—lung cancer	3.17e-06	4.21e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—TYMS—lung cancer	3.15e-06	4.19e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	3.15e-06	4.18e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PIK3CG—lung cancer	3.14e-06	4.17e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSTM1—lung cancer	3.12e-06	4.14e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CAT—lung cancer	3.11e-06	4.13e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—HPGDS—lung cancer	3.11e-06	4.13e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ENO2—lung cancer	3.11e-06	4.13e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PPP2R1B—lung cancer	3.09e-06	4.1e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CAT—lung cancer	3.08e-06	4.09e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PIK3CG—lung cancer	3.07e-06	4.08e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PIK3CG—lung cancer	3.07e-06	4.07e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	3.07e-06	4.07e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.04e-06	4.04e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CYP1A1—lung cancer	3.03e-06	4.02e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ABCB1—lung cancer	3.03e-06	4.02e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTT1—lung cancer	3.02e-06	4e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ERCC2—lung cancer	3e-06	3.99e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ABCB1—lung cancer	3e-06	3.98e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—POMC—lung cancer	2.99e-06	3.97e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP2A6—lung cancer	2.98e-06	3.96e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GCLC—lung cancer	2.98e-06	3.96e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—TYMS—lung cancer	2.97e-06	3.95e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CYP1A1—lung cancer	2.95e-06	3.92e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—TYMS—lung cancer	2.95e-06	3.91e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSTM1—lung cancer	2.94e-06	3.9e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—ERCC2—lung cancer	2.93e-06	3.89e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—STK11—lung cancer	2.93e-06	3.89e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—POMC—lung cancer	2.93e-06	3.88e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—POMC—lung cancer	2.92e-06	3.88e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTM1—lung cancer	2.91e-06	3.87e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CREBBP—lung cancer	2.91e-06	3.86e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PIK3CG—lung cancer	2.9e-06	3.85e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CREBBP—lung cancer	2.85e-06	3.78e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CREBBP—lung cancer	2.84e-06	3.78e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ENO1—lung cancer	2.83e-06	3.75e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PTEN—lung cancer	2.81e-06	3.73e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CYP1A1—lung cancer	2.78e-06	3.7e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ERCC2—lung cancer	2.76e-06	3.67e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CYP1A1—lung cancer	2.76e-06	3.67e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PIK3CD—lung cancer	2.76e-06	3.66e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—POMC—lung cancer	2.76e-06	3.66e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.75e-06	3.65e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ERCC2—lung cancer	2.74e-06	3.64e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—ALB—lung cancer	2.72e-06	3.62e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTP1—lung cancer	2.71e-06	3.6e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PIK3CD—lung cancer	2.7e-06	3.59e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PIK3CD—lung cancer	2.7e-06	3.58e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CREBBP—lung cancer	2.69e-06	3.57e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—EP300—lung cancer	2.68e-06	3.56e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—ALB—lung cancer	2.67e-06	3.54e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—ALB—lung cancer	2.66e-06	3.53e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CAT—lung cancer	2.63e-06	3.5e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.62e-06	3.48e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—APOA1—lung cancer	2.6e-06	3.45e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ABCB1—lung cancer	2.56e-06	3.4e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PIK3CD—lung cancer	2.55e-06	3.38e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—APOA1—lung cancer	2.54e-06	3.37e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP2E1—lung cancer	2.53e-06	3.36e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—TYMS—lung cancer	2.52e-06	3.34e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ALB—lung cancer	2.51e-06	3.34e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NQO1—lung cancer	2.51e-06	3.33e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTM1—lung cancer	2.49e-06	3.3e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.49e-06	3.3e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PIK3CB—lung cancer	2.4e-06	3.19e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—APOA1—lung cancer	2.39e-06	3.17e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PTGS2—lung cancer	2.38e-06	3.16e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PIK3CG—lung cancer	2.37e-06	3.15e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—APOA1—lung cancer	2.37e-06	3.14e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP1A1—lung cancer	2.36e-06	3.13e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PIK3CB—lung cancer	2.36e-06	3.13e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PIK3CB—lung cancer	2.35e-06	3.12e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ERCC2—lung cancer	2.34e-06	3.11e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PTGS2—lung cancer	2.33e-06	3.1e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PTGS2—lung cancer	2.33e-06	3.09e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PIK3CG—lung cancer	2.31e-06	3.07e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.27e-06	3.01e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—STK11—lung cancer	2.26e-06	3e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—POMC—lung cancer	2.26e-06	3e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PIK3CB—lung cancer	2.22e-06	2.95e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—POMC—lung cancer	2.2e-06	2.93e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PTGS2—lung cancer	2.2e-06	2.92e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CREBBP—lung cancer	2.2e-06	2.92e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PIK3CG—lung cancer	2.18e-06	2.9e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PIK3CG—lung cancer	2.16e-06	2.87e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CREBBP—lung cancer	2.15e-06	2.85e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTP1—lung cancer	2.09e-06	2.77e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PIK3CD—lung cancer	2.08e-06	2.77e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PTEN—lung cancer	2.08e-06	2.76e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—POMC—lung cancer	2.08e-06	2.76e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—POMC—lung cancer	2.06e-06	2.73e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ALB—lung cancer	2.06e-06	2.73e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PTEN—lung cancer	2.04e-06	2.7e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PIK3CD—lung cancer	2.03e-06	2.7e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CAT—lung cancer	2.03e-06	2.7e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PTEN—lung cancer	2.03e-06	2.7e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—APOA1—lung cancer	2.02e-06	2.69e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CREBBP—lung cancer	2.02e-06	2.69e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—ALB—lung cancer	2.01e-06	2.67e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CREBBP—lung cancer	2e-06	2.66e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PIK3CA—lung cancer	1.98e-06	2.63e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—EP300—lung cancer	1.98e-06	2.63e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ABCB1—lung cancer	1.98e-06	2.63e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—TYMS—lung cancer	1.94e-06	2.58e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—EP300—lung cancer	1.94e-06	2.58e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.94e-06	2.57e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—EP300—lung cancer	1.94e-06	2.57e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTM1—lung cancer	1.92e-06	2.55e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PTEN—lung cancer	1.92e-06	2.55e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PIK3CD—lung cancer	1.92e-06	2.55e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PIK3CD—lung cancer	1.9e-06	2.52e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ALB—lung cancer	1.89e-06	2.51e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ALB—lung cancer	1.88e-06	2.49e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PIK3CG—lung cancer	1.85e-06	2.45e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—EP300—lung cancer	1.83e-06	2.43e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP1A1—lung cancer	1.82e-06	2.42e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PIK3CB—lung cancer	1.82e-06	2.41e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ERCC2—lung cancer	1.81e-06	2.4e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PTGS2—lung cancer	1.8e-06	2.39e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PIK3CB—lung cancer	1.77e-06	2.35e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—POMC—lung cancer	1.76e-06	2.34e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PTGS2—lung cancer	1.76e-06	2.33e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CREBBP—lung cancer	1.71e-06	2.27e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PIK3CB—lung cancer	1.67e-06	2.22e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PIK3CB—lung cancer	1.66e-06	2.2e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PTGS2—lung cancer	1.66e-06	2.2e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PTGS2—lung cancer	1.64e-06	2.18e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PIK3CD—lung cancer	1.62e-06	2.16e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—AKT1—lung cancer	1.62e-06	2.15e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ALB—lung cancer	1.6e-06	2.13e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PTEN—lung cancer	1.57e-06	2.08e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—APOA1—lung cancer	1.56e-06	2.07e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PTEN—lung cancer	1.53e-06	2.03e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—EP300—lung cancer	1.5e-06	1.99e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PIK3CA—lung cancer	1.47e-06	1.95e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—EP300—lung cancer	1.46e-06	1.94e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PTEN—lung cancer	1.44e-06	1.92e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PIK3CA—lung cancer	1.44e-06	1.91e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PIK3CA—lung cancer	1.43e-06	1.9e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PTEN—lung cancer	1.43e-06	1.9e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PIK3CG—lung cancer	1.43e-06	1.89e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PIK3CB—lung cancer	1.42e-06	1.88e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PTGS2—lung cancer	1.4e-06	1.86e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—EP300—lung cancer	1.38e-06	1.83e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—EP300—lung cancer	1.37e-06	1.81e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—POMC—lung cancer	1.36e-06	1.8e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PIK3CA—lung cancer	1.35e-06	1.8e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CREBBP—lung cancer	1.32e-06	1.76e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PIK3CD—lung cancer	1.25e-06	1.66e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ALB—lung cancer	1.24e-06	1.64e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PTEN—lung cancer	1.22e-06	1.62e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—AKT1—lung cancer	1.2e-06	1.59e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—AKT1—lung cancer	1.17e-06	1.56e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—AKT1—lung cancer	1.17e-06	1.55e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—EP300—lung cancer	1.17e-06	1.55e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PIK3CA—lung cancer	1.11e-06	1.47e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—AKT1—lung cancer	1.11e-06	1.47e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PIK3CB—lung cancer	1.09e-06	1.45e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PTGS2—lung cancer	1.08e-06	1.44e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PIK3CA—lung cancer	1.08e-06	1.44e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PIK3CA—lung cancer	1.02e-06	1.35e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PIK3CA—lung cancer	1.01e-06	1.34e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PTEN—lung cancer	9.44e-07	1.25e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—AKT1—lung cancer	9.05e-07	1.2e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—EP300—lung cancer	9e-07	1.2e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—AKT1—lung cancer	8.83e-07	1.17e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PIK3CA—lung cancer	8.63e-07	1.15e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—AKT1—lung cancer	8.32e-07	1.11e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—AKT1—lung cancer	8.25e-07	1.1e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—AKT1—lung cancer	7.05e-07	9.36e-06	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PIK3CA—lung cancer	6.66e-07	8.84e-06	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—AKT1—lung cancer	5.44e-07	7.23e-06	CbGpPWpGaD
